Replies to post #7669 on PharmaCyte Biotech Inc (PMCB)

[DITRstocks]

Investors have mistaken silence in recent months from Nuvilex management for issues regarding its soon-to-be acquired partner SG Austria, when research collaboration is bearing significant fruit. The two are collaborating on key R&D projects, strengthening and broadening the reach of combined firms, which will substantially raise Nuvilex’s valuation.

$NVLX

[DITRstocks]

The current share price represents but a fraction of its true value, in our view. With recently increased interest and valuation in the pancreatic cancer treatment arena, we believe that Nuvilex is worth $0.20 just on the oncology therapies alone and that the shares will reach $0.50 in the next six months. Looking ahead, as milestone events occur, $1.00 per share is within reach over the next 12-18 months. Thus, we reiterate our Speculative Buy rating.

$NVLX